Trial Profile

Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegfilgrastim (Primary)
Indications Febrile neutropenia
Focus Registrational; Therapeutic Use
Acronyms PROTECT2
Sponsors Sandoz

Most Recent Events

07 Jun 2016 Results of a pooled analysis from PROTECT1 and PROTECT2 trials (n=624) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
23 Jan 2016 Primary endpoint has been met. (Mean duration of Grade 4 neutropenia during Cycle 1 of chemotherapy)
08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com